How is von Hippel-Lindau syndrome inherited?
How is VHL inherited? Normally, every cell has 2 copies of each gene: 1 inherited from the mother and 1 inherited from the father. VHL follows an autosomal dominant inheritance pattern, in which inheriting 1 copy of the altered gene will likely result in a mutation of the second (normal) copy of the gene.
Is Belzutifan FDA approved?
A new drug recently approved by the Food and Drug Administration (FDA) may help people with VHL avoid or delay surgery by shrinking their tumors. On August 13, FDA approved belzutifan (Welireg) to treat adults who have several tumors associated with VHL.
Can Von Hippel-Lindau skip a generation?
Some people who have inherited a germline VHL mutation never develop cancer. This is because they never get the second mutation necessary to knock out the function of the gene and start the process of tumor formation. This can make the cancer appear to skip generations in a family.
Can von Hippel-Lindau syndrome be prevented?
As an autosomal dominant disorder, VHL cannot be prevented once an individual has the mutation. Genetic counseling of patients with VHL who wish to have children should be provided. Testing for a VHL mutation in a fetus is possible with amniocentesis or chorionic villus sampling.
Can someone with von Hippel-Lindau syndrome have children?
These children are the first in their families to have von Hippel-Lindau syndrome. No matter how they acquired the VHL mutation, people with von Hippel-Lindau syndrome have a 50% or 1 in 2 chance of passing it on to their children.
Is VHL fatal?
Conclusions: vHL survival has improved over time and has become closer to that of siblings without vHL and the general population. Even though the risk of vHL-related death has decreased significantly, the main cause of death is still CNS hemangioblastomas and hence improved treatment options are essential.
How is belzutifan administered?
The recommended belzutifan dosage is 120 mg administered orally once daily with or without food.
What is belzutifan used for?
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.
What is the VHL gene?
The VHL gene provides instructions for making a protein that functions as part of a complex (a group of proteins that work together) called the VCB-CUL2 complex. This complex targets other proteins to be broken down (degraded) by the cell when they are no longer needed.
Where is the VHL gene?
Von Hippel-Lindau (VHL) disease is characterized by heterozygous germline mutation in VHL gene on chromosome 3p.
What is the life expectancy of von Hippel-Lindau?
Owing largely to the high incidence of clear cell renal cell carcinoma associated with von Hippel-Lindau (VHL) disease, the average life expectancy in affected individuals is 49 years. However, diligent surveillance enabling early treatment interventions can increase life expectancy.
What are the treatments for VHL?
Treatment of most cases of VHL usually involves surgery to remove the tumors before they become harmful. Certain tumors can be treated with focused high-dose irradiation. Individuals with VHL need careful monitoring by a physician and/or medical team familiar with the disorder.
https://www.youtube.com/watch?v=v6cJB43iwyE